CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Carfilzomib, a proteasome inhibitor, is approved in the United States as a single agent, and in combination with dexamethasone or lenalidomide/dexamethasone (KRd) for relapsed or refractory multiple myeloma (MM). Under the single-agent and KRd approvals, carfilzomib is administered as a 10-minute IV...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Berenson, James R., Cartmell, Alan, Bessudo, Alberto, Lyons, Roger M., Harb, Wael, Tzachanis, Dimitrios, Agajanian, Richy, Boccia, Ralph, Coleman, Morton, Moss, Robert A., Rifkin, Robert M., Patel, Priti, Dixon, Sandra, Ou, Ying, Anderl, Janet, Aggarwal, Sanjay, Berdeja, Jesus G.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2016
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4929927/
https://ncbi.nlm.nih.gov/pubmed/27207788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-683854
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares